101 related articles for article (PubMed ID: 27339486)
1. Expression and clinicopathological correlations of retinoid acid receptor responder protein 1 in renal cell carcinomas.
Zimpfer A; Dammert F; Glass A; Zettl H; Kilic E; Maruschke M; Hakenberg OW; Erbersdobler A
Biomark Med; 2016 Jul; 10(7):721-32. PubMed ID: 27339486
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
3. Expression and Clinical Significance of SOX9 in Renal Cell Carcinoma, Bladder Cancer and Penile Cancer.
Wan YP; Xi M; He HC; Wan S; Hua W; Zen ZC; Liu YL; Zhou YL; Mo RJ; Zhuo YJ; Luo HW; Jiang FN; Zhong WD
Oncol Res Treat; 2017; 40(1-2):15-20. PubMed ID: 28118628
[TBL] [Abstract][Full Text] [Related]
4. Anillin expression is a marker of favourable prognosis in patients with renal cell carcinoma.
Ronkainen H; Hirvikoski P; Kauppila S; Vaarala MH
Oncol Rep; 2011 Jan; 25(1):129-33. PubMed ID: 21109967
[TBL] [Abstract][Full Text] [Related]
5. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma.
Gremel G; Djureinovic D; Niinivirta M; Laird A; Ljungqvist O; Johannesson H; Bergman J; Edqvist PH; Navani S; Khan N; Patil T; Sivertsson Å; Uhlén M; Harrison DJ; Ullenhag GJ; Stewart GD; Pontén F
BMC Cancer; 2017 Jan; 17(1):9. PubMed ID: 28052770
[TBL] [Abstract][Full Text] [Related]
6. Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival.
Zhang Y; Li J; Song Y; Chen F; Pei Y; Yao F
Mol Med Rep; 2014 Aug; 10(2):860-6. PubMed ID: 24913320
[TBL] [Abstract][Full Text] [Related]
7. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
8. Expression of RARRES1 and AGBL2 and progression of conventional renal cell carcinoma.
Peterfi L; Banyai D; Yusenko MV; Bjercke T; Kovacs G
Br J Cancer; 2020 Jun; 122(12):1818-1824. PubMed ID: 32307444
[TBL] [Abstract][Full Text] [Related]
9. CD1d expression in renal cell carcinoma is associated with higher relapse rates, poorer cancer-specific and overall survival.
Chong TW; Goh FY; Sim MY; Huang HH; Thike AA; Lim WK; Teh BT; Tan PH
J Clin Pathol; 2015 Mar; 68(3):200-5. PubMed ID: 25477528
[TBL] [Abstract][Full Text] [Related]
10. Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma.
Shimazui T; Kojima T; Onozawa M; Suzuki M; Asano T; Akaza H
Oncol Rep; 2006 May; 15(5):1181-4. PubMed ID: 16596183
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: A case-control study and meta-analysis.
Liu Q; Zhang GW; Zhu CY; Wei JX; Tian X; Li Y; Li XD
Cancer Biomark; 2016; 16(2):281-9. PubMed ID: 26756619
[TBL] [Abstract][Full Text] [Related]
12. The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma.
Sun D; Lu J; Ding K; Bi D; Niu Z; Cao Q; Zhang J; Ding S
Med Oncol; 2013 Mar; 30(1):476. PubMed ID: 23371254
[TBL] [Abstract][Full Text] [Related]
13. Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.
Jorns J; Thiel DD; Lohse CM; Williams A; Arnold ML; Cheville JC; Leibovich BC; Parker AS
BJU Int; 2012 Oct; 110(7):956-60. PubMed ID: 22300498
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of extensive necrosis in renal cell carcinoma.
Collins J; Epstein JI
Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
[TBL] [Abstract][Full Text] [Related]
15. Neovascularity as a prognostic marker in renal cell carcinoma.
Bauman TM; Huang W; Lee MH; Abel EJ
Hum Pathol; 2016 Nov; 57():98-105. PubMed ID: 27436827
[TBL] [Abstract][Full Text] [Related]
16. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma.
Yao M; Tabuchi H; Nagashima Y; Baba M; Nakaigawa N; Ishiguro H; Hamada K; Inayama Y; Kishida T; Hattori K; Yamada-Okabe H; Kubota Y
J Pathol; 2005 Feb; 205(3):377-87. PubMed ID: 15682440
[TBL] [Abstract][Full Text] [Related]
17. Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters.
Tsai WC; Sheu LF; Nieh S; Yu CP; Sun GH; Lin YF; Chen A; Jin JS
World J Urol; 2007 Mar; 25(1):73-80. PubMed ID: 17021824
[TBL] [Abstract][Full Text] [Related]
18. Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.
Cheville JC; Lohse CM; Sukov WR; Thompson RH; Leibovich BC
Am J Surg Pathol; 2012 Jun; 36(6):851-6. PubMed ID: 22367296
[TBL] [Abstract][Full Text] [Related]
19. Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation.
Ku JH; Park YH; Myung JK; Moon KC; Kwak C; Kim HH
Urol Oncol; 2011; 29(6):731-7. PubMed ID: 19914104
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
